Circulatory estrogen level protects against breast cancer in obese women

Recent Patents on Anti-Cancer Drug Discovery

Volumn 8, Issue 2, 2013, Pages 154-167

  Suba, Zsuzsanna ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

Androgen; Breast cancer risk; Estrogen; Insulin resistance; Menopause; Metabolic syndrome; Obesity; Type 2 diabetes; Visceral adiposity

Indexed keywords

ESTROGEN; ORAL CONTRACEPTIVE AGENT; PHYTOESTROGEN;

ANOVULATION; ANTIDIABETIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; DISEASE ASSOCIATION; ESTROGEN BLOOD LEVEL; ESTROGEN SYNTHESIS; ESTROGEN THERAPY; FEMALE INFERTILITY; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; INSULIN RESISTANCE; MENOPAUSE; MENSTRUAL CYCLE; METABOLIC DISORDER; METABOLIC SYNDROME X; OBESITY; OVARY POLYCYSTIC DISEASE; PATENT; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR;

EID: 84875303874     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574892811308020004     Document Type: Article

References (186)

1. Rose DP, Vona-Davis L. Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas 2010; 66(1): 33-8.
2. Franceschi S, Favero A, La Vecchia C, Barón AE, Negri E, Dal Maso L, et al. Body size indices and breast cancer risk before and after menopause. Int J Cancer 1996; 67(2): 181-6.
3. Ursin G, Longnecker MP, Haile RW, Greenland S. A meta-analysis of body mass index and risk of premenopausal breast cancer. Epidemiology 1995; 6(2): 137-41.
4. Suzuki R, Iwasaki M, Inoue M, Sasazuki S, Sawada N, Yamaji T, et al. Body weight at age 20 years, subsequent weight change and breast cancer risk defined by estrogen and progesterone receptor status-the Japan public health center-based study. Int J Cancer 2011; 129(5): 1214-24.
5. Baer HJ, Tworoger SS, Hankinson SE, Willett WC. Body fatness at young ages and risk of breast cancer throughout life. Am J Epidemiol 2010; 171(11): 1183-94.
6. La Vecchia C, Negri E, Franceschi S, Talamini R, Bruzzi P, Palli D, et al. Body mass index and postmenopausal breast cancer: An age specific analysis. Br J Cancer 1997; 75(3): 441-4.
7. Potischman N, Swanson CA, Siiteri P, Hoover RN. Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst 1996; 88(11): 756-8.
8. Rose DP, Vona-Davis I. Influence of obesity on breast cancer receptor status and prognosis. Expert Rev Anticancer Ther 2009; 9(8): 1091-1.
9. Vona-Davis I, Howard-McNatt M, Rose DP. Adiposity, type-2 diabetes and the metabolic syndrome in breast cancer. Obes Rev 2007; 8(5): 395-408.
10. Key T, Appleby P, Barnes I, Reeves G. Endogenous hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94(8): 606-16.
11. International Agency for Research on Cancer. Monographs on the evaluation of carcinogenic risks to humans: Hormonal contraception and postmenopausal hormone therapy. IARC, vol. 72, Lyon, France, 1999.
12. Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw KT, Tehard B, et al. Body size and breast cancer risk: Findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2004; 111(5): 762-71.
13. Howell A, Chapman M, Harvie M. Energy restriction for breast cancer prevention. Recent Results Cancer Res 2009; 181: 97-111.
14. Huang Z, Willett WC, Colditz GA, Hunter DJ, Manson JE, Rosner B, et al. Waist circumference, waist:hip ratio, and risk of breast cancer in the Nurses' Health Study. Am J Epidemiol 1999; 150(12): 1316-24.
15. Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L, et al. Obesity, body size and risk of postmenopausal breast cancer: The Women's Health Initiative (United States). Cancer Causes Control 2002; 13(8): 41-51.
16. Zain MM, Norman RJ. Impact of obesity on female fertility and fertility treatment. Womens Health (Lond Engl) 2008; 4(2): 183-94.
17. Stephenson GD, Rose DP. Breast cancer and obesity: An update. Nutr Cancer 2003; 45(1): 1-16.
18. Althuis MD, Brogan DD, Coates RJ, Gammon MD, Malone KE, Schoenberg JB, et al. Breast cancers among very young premenopausal women (United States). Cancer Causes Control 2003; 14(2): 151-60.
19. Suba Z. Interplay between insulin resistance and estrogen deficiency as co-activators in carcinogenesis. Pathol Oncol Res 2012; 18(2): 123-33.
20. Suba Z. Insulin resistance, estrogen deficiency and cancer risk. In: Suba Z. Ed. Estrogen versus Cancer. New York, Nova Science Publishers Inc., 2009, pp. 127-46.
21. Suba Z. Obesity and risk for salivary gland tumors. In: Ramonde PR, Fochas EH. Eds. Obesity and cancer research. New York, Nova Science Publishers Inc., 2009, pp. 71-86.
22. Björntorp P. The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord 1996; 20(4): 291-302.
23. Reaven GM. Banting lecture 1988: Role of insulin resistance in human disease. Diabetes 1988; 37(12): 1595-607.
24. Bloomgarden ZT. Second World Congress on the Insulin Resistance Syndrome: Mediators, pediatric insulin resistance, the polycystic ovary syndrome, and malignancy. Diab Care 2005; 28(8): 1821-30.
25. Gupta K, Krishnaswamy G, Karnad A, Peiris A. Insulin: A novel factor in carcinogenesis. Am J Med Sci 2002; 323(3): 140-5.
26. Yu H, Rohan T. Role of insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92(18): 1472-89.
27. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al. Insulin, insulin-like growth factor and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009; 101(1): 48-60.
28. Kleinberg, D.L. Somatostatin analogs and IGF-I inhibition for breast cancer prevention. US20090325863 (2009).
29. Reaven GM. Insulin resistance, cardiovascular disease, and the metabolic syndrome: How well do the emperor's clothes fit? Diabetes Care 2004; 27(4): 1011-2.
30. Cowey S, Hardy RW. The metabolic syndrome. A high risk state for cancer? Am J Pathol 2006; 169(5): 1505-22.
31. Doyle SL, Donohoe CL, Lysaght J, Reynolds JV. Visceral obesity, metabolic syndrome, insulin resistance and cancer. Proc Nutr Soc 2012; 71(1): 181-9.
32. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm. Diabetes 1999; 48(1): 1-9.
33. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999; 24(2): 68-72.
34. Brownlee M. Lilly Lecture 1993. Glycation and diabetic complications. Diabetes 1994; 43(6): 836-41.
35. Sieri S, Muti P, Claudia A, Berrino F, Pala V, Grioni S, et al. Prospective study on the role of glucose metabolism in breast cancer occurrence. Int J Cancer 2012; 130(4): 921-9.
36. Reaven GM. Role of insulin resistance in human disease (syndrome X): An expanded definition. Annu Rev 1993; 44: 121-31.
37. McKeown-Eyssen G. Epidemiology of colorectal cancer revisited: Are serum triglycerides and plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev 1994; 3(8): 687-95.
38. Welsch CW. Relationship between dietary fat and experimental mammary tumorigenesis: A review and critique. Cancer Res 1992; 52(7 Suppl): 2040s-8s.
39. Muti P, Quattrin T, Grant BJ, Krogh V, Micheli A, Schunemann HJ, et al. Fasting glucose is a risk factor for breast cancer: A prospective study. Cancer Epidemiol Biomarkers Prev 2002; 11(11): 1361-8.
40. Landsberg L. Insulin mediated sympathetic stimulation: Role in the pathogenesis of obesity related hypertension (or how insulin affects blood pressure and why). Hypertension 2001; 19(3): 523-8.
41. Goff DC Jr, Zaccaro DJ, Haffner SM, Saad MF. Insulin sensitivity and risk the risk of incident hypertension: Insights from the insulin resistance atherosclerosis study. Diabetes Care 2003; 26(3): 805-9.
42. Takatori S, Zamami Y, Mio M, Kurosaki Y, Kawasaki H. Chronic hyperinsulinemia enhances adrenergic vasoconstriction and decreases calcitonin gene-related peptide-containing nerve-mediated vasodilation in pithed rats. Hypertens Res 2006; 29(5): 361-8.
43. Cooper SA, Whaley-Connell A, Habibi J, Wei Y, Lastra G, Manrique C, et al. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 2007; 293(4): H2009-23.
44. Soler M, Chatenoud L, Negri E, Parazzini F, Franceschi S, La Vecchia C. Hypertension and hormone-related neoplasms in women. Hypertension 1999; 34(2): 320-5.
45. Rosato V, Bosetti C, Talamini R, Levi F, Negri E, La Vecchia C. Metabolic syndrome and the risk of breast cancer. Recenti Prog Med 2011; 102(12): 476-8.
46. Healy LA, Ryan AM, Carroll P, Ennis D, Crowley V, Boyle T, et al. Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin Oncol (R Coll Radiol) 2010; 22(4): 281-8.
47. Kabat GC, Kim M, Chlebowski RT, Khandekar J, Ko MG, McTiernan A, et al. A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2009; 18(7): 2046-53.
48. Altomare E, Vendemiale G, Chicco D, Procacci V, Cirelli F. Increased lipid peroxidation in type 2 poorly controlled diabetic patients. Diabetes Metab 1992; 18(4): 264-71.
49. Tsuji S, Kawai N, Tsujii M, Kawano S, Hori M. Review article: Inflammation-related promotion of gastrointestinal carcinogenesis--a perigenetic pathway. Aliment Pharmacol Ther 2003; 18(Suppl 1): 82-9.
50. Munkholm P. Review article: The incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18(Suppl 2): 1-5.
51. Grote VA, Becker S, Kaaks R. Diabetes mellitus type 2-an independent risk factor for cancer? Exp Clin Endocrinol Diabetes 2010; 118(1): 4-8.
52. La Vecchia C, Giordano SH, Hortobagyi GN, Chabner B. Overweight, obesity, diabetes, and risk of breast cancer: Interlocking pieces of the puzzle. Oncologist 2011; 16(6): 726-9.
53. Arif JM, Al-Saif AM, Al-Karrawi MA, Al-Sagair OA. Causative relationship between diabetes mellitus and breast cancer in various regions of Saudi Arabia: An overview. Asian Pac J Cancer Prev 2011; 12(3): 589-92.
54. Baselga, J., Di Cosimo, S., Garcia-Echeverria, C., Hackl, W., Maira, S.M., Michelangelo, R., Elizalde, V.S. Combination of (A) a phosphoinositide 3-kinase inhibitor and (B) an antidiabetic compound for use in the treatment of proliferative diseases. US20120059005 (2012).
55. Sartor BM, Dickey RP. Polycystic ovarian syndrome and the metabolic syndrome. Am J Med Sci 2005; 330(6): 336-42.
56. Nestler JE. Obesity, insulin, sex steroids and ovulation. Int J Obes Relat Metab Disord 2000; 24 (Suppl 2): S71-3.
57. Cara JF, Rosenfield RL. Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology 1988; 123(2): 733-9.
58. Nestler JE, Jakubowicz DJ, deVargas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998; 83(6): 2001-5.
59. Attia GR, Rainey WE, Carr BR. Metformin directly inhibits androgen production in human thecal cells. Fertil Steril 2001; 76(3): 517-24.
60. Kim, S.W., Jun, S.S., Jo, Y.G., Koo, J.S., Kim, Y.W. N, N-Dimethyl imidodicarbonimidic diamide acetate method for producing the same and pharmaceutical composition comprising the same. US20120010287 (2012).
61. Moghetti P, Castello R, Negri C, Tosi F, Spiazzi GG, Brun E, et al. Insulin infusion amplifies 17 alpha-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J Clin Endocrinol Metab 1996; 81(3): 881-6.
62. Cara JF, Fan J, Azzarello J, Rosenfield RL. Insulin-like growth factor-I enhances luteinizing hormone binding to rat ovarian thecainterstitial cells. J Clin Invest 1990; 86(2): 560-5.
63. Kaaks R. Nutrition, hormones, and breast cancer: Is insulin the missing link? Cancer Causes Control 1996; 7(6): 605-25.
64. Secreto G, Zumoff B. Abnormal production of androgens in women with breast cancer. Anticancer Res 1994; 14(5B): 2113-7.
65. Micheli A, Muti P, Secreto G, Krogh V, Meneghini E, Venturelli E, et al. Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer 2004; 112(2): 312-8.
66. Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol 2003; 86(3-5): 225-30.
67. Suba Z. The role of estrogen in health and disease. In: Suba Z. Ed. Estrogen versus Cancer. New York, Nova Science Publishers Inc., 2009, pp. 59-84.
68. Stamataki KE, Spina J, Rangou DB, Chlouverakis CS, Piaditis GP. Ovarian function in women with non-insulin dependent diabetes mellitus. Clin Endocrinol (Oxf) 1996; 45(5): 615-21.
69. MacGillivray MH, Morishima A, Conte F, Grumbach M, Smith EP. Pediatric endocrinology update: An overview. The essential roles of estrogens in pubertal growth, epiphyseal fusion and bone turnover: Lessons from mutations in the genes for aromatase and the estrogen receptor. Horm Res 1998; 49 (Suppl 1): 2-8.
70. Alemany M. Do the interactions between glucocorticoids and sex hormones regulate the development of the metabolic syndrome? Front Endocrinol (Lausanne) 2012; 3: 27.
71. Donohoe CL, Doyle SL, Reynolds JV. Visceral adiposity, insulin resistance and cancer risk. Diabetol Metab Syndr 2011; 3: 12.
72. Jacobi D, Stanya KJ, Lee CH. Adipose tissue signaling by nuclear receptors in metabolic complications of obesity. Adipocyte 2012; 1(1): 4-12.
73. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89(6): 2548-56.
74. Heemskerk VH, Daemen MA, Buurman WA. Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation. Cytokine Growth Factor Rev 1999; 10(1): 5-14.
75. Arcidiacono B, Iiritano S, Nocera A, Possidente K, Nevolo MT, Ventura V. Insulin resistance and cancer risk: An overview of the pathogenetic mechanisms. Exp Diabetes Res 2012; 2012: 789174.
76. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115(5): 911-9.
77. Cirillo D, Rachiglio AM, la Montagna R, Giordano A, Normanno N. Leptin signaling in breast cancer: An overview. J Cell Biochem 2008; 105(4): 956-64.
78. Schäffler A, Schölmerich J, Buechler C. Mechanisms of disease: Adipokines and breast cancer-endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat Clin Pract Endocrinol Metab 2007; (4): 345-54.
79. Grossmann ME, Cleary MP. The balance between leptin and adiponectin in the control of carcinogenesis-focus on mammary tumorigenesis. Biochimie 2012; 94(10): 2164-71.
80. Celis JE, Moreira JM, Cabezón T, Gromov P, Friis E, Rank F, et al. Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: Toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Mol Cell Proteomics 2005; 4(4): 492-522.
81. Goldberg JE, Schwertfeger KL. Proinflammatory cytokines in breast cancer: Mechanisms of action and potential targets for therapeutics. Curr Drug Targets 2010; 11(9): 1133-46.
82. Pallottini V, Bulzomi P, Galluzzo P, Martini C, Marino M. Estrogen regulation of adipose tissue functions: Involvement of estrogen receptor isoforms. Infect Disord Drug Targets 2008; 8(1): 52-60.
83. Macotela Y, Boucher J, Tran TT, Kahn CR. Sex and depot differences in adipocyte insulin sensitivity and glucose metabolism. Diabetes 2009; 58(4): 803-12.
84. Poehlman ET, Toth MJ, Gardner AW. Changes in energy balance and body composition at menopause: A controlled longitudinal study. Ann Intern Med 1995; 123(9): 673-5.
85. Choi SB, Jang JS, Park S. Estrogen and exercise may enhance betacell function and mass via insulin receptor substrate 2 induction in ovariectomized diabetic rats. Endocrinology 2005; 146(11): 4786-94.
86. Tagawa N, Yuda R, Kubota S, Wakabayashi M, Yamaguchi Y, Kiyonaga D, et al. 17Beta-estradiol inhibits 11beta-hydroxysteroid dehydrogenase type 1 activity in rodent adipocytes. J Endocrinol 2009; 202(1): 131-9.
87. Baghaei F, Rosmond R, Westberg L, Hellstrand M, Eriksson E, Holm G, et al. The CYP19 gene and associations with androgens and abdominal obesity in premenopausal women. Obes Res 2003; 11(4): 578-85.
88. Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Nestler JE. A modern medical quandary: Polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 2003; 88(5): 1927-32.
89. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: Effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006; 8(5): 538-54.
90. Reckelhoff JF. Sex steroids, cardiovascular disease, and hypertension: unanswered questions and some speculations. Hypertension 2005; 45(2): 170-4.
91. Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas 1990; 12(4): 321-31.
92. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325(17): 1196-204.
93. Hamden K, Carreau S, Ellouz F, Masmoudi H, El FA. Protective effect of 17beta-estradiol on oxidative stress and liver dysfunction in aged male rats. J Physiol Biochem 2007; 63(3): 195-201.
94. Harrison-Bernard LM, Schulman IH, Raij L. Postovariectomy hypertension is linked to increased renal AT1 receptor and salt sensitivity. Hypertension 2003; 42(6): 1157-63.
95. Gallagher PE, Li P, Lenhart JR, Chappell MC, Brosnihan KB. Estrogen regulation of angiotensin-converting enzyme mRNA. Hypertension 1999; 33(1 Pt 2): 323-8.
96. Widder J, Pelzer T, von Poser-Klein C, Hu K, Jazbutyte V, Fritzemeier KH, et al. Improvement of endothelial dysfunction by selective estrogen receptor-alpha stimulation in ovariectomized SHR. Hypertension 2003; 42(5): 991-6.
97. Yanes LL, Reckelhoff JF. Postmenopausal hypertension. Am J Hypertens 2011; 24(7): 740-9.
98. Dantas AP, Tostes RC, Fortes ZB, Costa SG, Nigro D, Carvalho MH. In vivo evidence for antioxidant potential of estrogen in microvessels of female spontaneously hypertensive rats. Hypertension 2002; 39(2 Pt 2): 405-11.
99. Viña J, Sastre J, Pallardó FV, Gambini J, Borrás C. Role of mitochondrial oxidative stress to explain the different longevity between genders: Protective effect of estrogens. Free Radic Res 2006; 40(12): 1359-65.
100. Barros RP, Machado UF, Gustafsson JA. Estrogen receptors: New players in diabetes mellitus. Trends Mol Med 2006; 12(9): 425-31.
101. Tiano JP, Mauvais-Jarvis F. Importance of oestrogen receptors to preserve functional α-cell mass in diabetes. Nat Rev Endocrinol 2012; 8(6): 342-51.
102. Bryzgalova G, Gao H, Ahren B, Zierath JR, Galuska D, Steiler TL, et al. Evidence that oestrogen receptor-alpha plays an important role in the regulation of glucose homeostasis in mice: Insulin sensitivity in the liver. Diabetologia 2006; 49(3): 588-97.
103. Nagira K, Sasaoka T, Wada T, Fukui K, Ikubo M, Hori S, et al. Altered subcellular distribution of estrogen receptor alpha is implicated in estradiol-induced dual regulation of insulin signaling in 3T3-L1 adipocytes. Endocrinology 2006; 147(2): 1020-8.
104. Welch RD, Gorski J. Regulation of glucose transporters by estradiol in the immature rat uterus. Endocrinology 1999; 140(8): 3602-8.
105. Rosenbaum D, Haber RS, Dunaif A. Insulin resistance in polycystic ovary syndrome: Decreased expression of GLUT-4 glucose transporters in adipocytes. Am J Physiol 1993; 264(2 Pt 1): E197-202.
106. Leung KC, Johannsson G, Leong GM, Ho KK. Estrogen regulation of growth hormone action. Endocr Rev 2004; 25(5): 693-721.
107. Abu-Taha M, Rius C, Hermenegildo C, Noguera I, Cerda-Nicolas JM, Issekutz AC. Menopause and ovariectomy cause a low grade of systemic inflammation that may be prevented by chronic treatment with low doses of estrogen or losartan. J Immunol 2009; 183(2): 1393-402.
108. Geraldes P, Sirois MG, Tanguay JF. Specific contribution of estrogen receptors on mitogen-activated protein kinase pathways and vascular cell activation. Circ Res 2003; 93(5): 399-405.
109. Llaneza P, González C, Fernandez-Iñarrea J, Alonso A, Diaz F, Arnott I, et al. Soy isoflavones, diet and physical exercise modify serum cytokines in healthy obese postmenopausal women. Phytomedicine 2011; 18(4): 245-50.
110. Adlercreutz HJ. Phytoestrogens and breast cancer. Steroid Biochem Mol Biol 2002; 83(1-5): 113-8.
111. Veldhuis JD, Frystyk J, Iranmanesh A, Ørskov H. Testosterone and estradiol regulate free insulin-like growth factor I (IGF-I), IGF binding protein 1 (IGFBP-1), and dimeric IGF-I/IGFBP-1 concentrations. J Clin Endocrinol Metab 2005; 90(5): 2941-7.
112. Smith CL. Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol Reprod 1998; 58(3): 627-32.
113. Xu J, Xiang Q, Lin G, Fu X, Zhou K, Jiang P, et al. Estrogen improved metabolic syndrome through down-regulation of VEGF and HIF-1α to inhibit hypoxia of periaortic and intra-abdominal fat in ovariectomized female rats. Mol Biol Rep 2012; 39(8): 8177-85.
114. Driggers PH, Segars JH. Estrogen action and cytoplasmic signaling pathways. Part II: The role of growth factors and phosphorylation in estrogen signaling. Trends Endocrinol Metab 2002; 13(10): 422-7.
115. Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer: Exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer 2006; 13 Suppl 1: S15-24.
116. Stoica A, Saceda M, Doraiswamy VL, Coleman C, Martin MB. Regulation of estrogen receptor-alpha gene expression by epidermal growth factor. J Endocrinol 2000; 165(2): 371-8.
117. Nedungadi TP, Clegg DJ. Sexual dimorphism in body fat distribution and risk for cardiovascular diseases. J Cardiovasc Transl Res 2009; 2(3): 321-7.
118. Michels KB, Terry KL, Willett WC. Longitudinal study on the role of body size in premenopausal breast cancer. Arch Intern Med 2006; 166(21): 2395-402.
119. Harris HR, Willett WC, Terry KL, Michels KB. Body fat distribution and risk of premenopausal breast cancer in the Nurses' Health Study II. J Natl Cancer Inst 2011; 103(3): 273-8.
120. Sonnenschein E, Toniolo P, Terry MB, Bruning PF, Kato I, Koenig KL, et al. Body fat distribution and obesity in pre-and postmenopausal breast cancer. Int J Epidemiol 1999; 28(6): 1026-31.
121. Page JH, Rexrode KM, Hu F, Albert CM, Chae CU, Manson JE. Waist-height ratio as a predictor of coronary heart disease among women. Epidemiology 2009; 20(3): 361-6.
122. Fagherazzi G, Chabbert-Buffet N, Fabre A, Guillas G, Boutron-Ruault MC, Mesrine S, et al. Hip circumference is associated with the risk of premenopausal ER-/PR-breast cancer. Int J Obes (Lond) 2012; 36(3): 431-9.
123. Caprio S, Hyman LD, Limb C, McCarthy S, Lange R, Sherwin RS, et al. Central adiposity and its metabolic correlates in obese adolescent girls. Am J Physiol 1995; 269(1 Pt 1): E118-26.
124. Gurtcheff SE, Klein NA. Diminished ovarian reserve and infertility. Clin Obstet Gynecol 2011; 54(4): 666-74.
125. Tobisch B, Blatniczky L, Barkai L. Correlation between insulin resistance and puberty in children with increased cardiometabolic risk. Orv Hetil 2011; 152(27): 1068-74.
126. Theintz G. From obesity to type-2 diabetes in children and adolescents. Rev Med Suisse 2005; 1(7): 477-80.
127. Berkey CS, Frazier AL, Gardner JD, Colditz GA. Adolescence and breast carcinoma risk. Cancer 1999; 85(11): 2400-9.
128. Bardia A, Vachon CM, Olson JE, Vierkant RA, Wang AH, Hartmann LC, et al. Relative weight at age 12 and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17(2): 374-8.
129. Stoll BA. Teenage obesity in relation to breast cancer risk. Int J Obes Relat Metab Disord 1998; 22(11): 1035-40.
130. Colditz GA, Frazier AL. Models of breast cancer show that risk is set by events of early life: Prevention efforts must shift focus. Cancer Epidemiol Biomarkers Prev 1995; 4(5): 567-71.
131. Pilia S, Casini MR, Foschini ML, Minerba L, Musiu MC, Marras V, et al. The effect of puberty on insulin resistance in obese children. J Endocrinol Invest 2009; 32(5): 401-5.
132. Vanhala MJ, Vanhala PT, Keinänen-Kiukaanniemi SM, Kumpusalo EA, Takala JK. Relative weight gain and obesity as a child predict metabolic syndrome as an adult. Int J Obes Relat Metab Disord 1999; 23(6): 656-9.
133. Apter D, Vihko R. Endocrine determinants of fertility: Serum androgen concentrations during follow-up of adolescents into the third decade of life. J Clin Endocrinol Metab 1990; 71(4): 970-4.
134. Baer HJ, Colditz GA, Willett WC, Dorgan JF. Adiposity and sex hormones in girls. Cancer Epidemiol Biomarkers Prev 2007; 16(9): 1880-8.
135. Velentgas P, Daling JR. Risk factors for breast cancer in younger women. J Natl Cancer Inst Monogr 1994; (16): 15-24.
136. Suba Z. Common soil of smoking-associated and hormone-related cancers: Estrogen deficiency. Oncol Rev 2010; 4(2): 73-87.
137. Terry KL, Willett WC, Rich-Edwards JW, Hunter DJ, Michels KB. Menstrual cycle characteristics and incidence of premenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2005; 14(6): 1509-13.
138. Whelan EA, Sandler DP, Root JL, Smith KR, Weinberg CR. Menstrual cycle patterns and risk of breast cancer. Am J Epidemiol 1994; 140(12): 1081-90.
139. Yuan JM, Yu MC, Ross RK, Gao YT, Henderson BE. Risk factors for breast cancer in Chinese women in Shanghai. Cancer Res 1988; 48(7): 1949-53.
140. Clavel-Chapelon F. Cumulative number of menstrual cycles and breast cancer risk: Results from the E3N cohort study of French women. Cancer Causes Control 2002; 13(9): 831-8.
141. Titus-Ernstoff L, Longnecker MP, Newcomb PA, Dain B, Greenberg ER, Mittendorf R, et al. Menstrual factors in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998; 7(9): 783-9.
142. Gao YT, Shu XO, Dai Q, Potter JD, Brinton LA, Wen W, et al. Association of menstrual and reproductive factors with breast cancer risk: Results from the Sanghai Breast Cancer Study. Int J Cancer 2000; 87(2): 295-300.
143. den Tonkelaar I, de Waard F. Regularity and length of menstrual cycles in women aged 41-46 in relation to breast cancer risk: Results from the DOM-project. Breast Cancer Res Treat 1996; 38(3): 253-8.
144. Wu AH, Ziegler RG, Pike MC, Nomura AM, West DW, Kolonel LN, et al. Menstrual and reproductive factors and risk of breast cancer in Asian-Americans. Br J Cancer 1996; 73(5): 680-6.
145. Parazzini F, La Vecchia C, Negri E, Franceschi S, Tozzi L. Lifelong menstrual patterns and risk of breast cancer. Oncology 1993; 50(4): 222-5.
146. Terry KL, Willett WC, Rich-Edwards JW, Michels KB. A prospective study of infertility due to ovulatory disorders, ovulation induction, and incidence of breast cancer. Arch Intern Med 2006; 166(22): 2484-9.
147. Gadducci A, Gargini A, Palla E, Fanucchi A, Genazzani AR. Polycystic ovary syndrome and gynecological cancers: Is there a link? Gynecol Endocrinol 2005; 20(4): 200-8.
148. de França Neto AH, Rogatto S, Do Amorim MMR, Tamanaha S, Aoki T, Aldrighi JM. Oncological repercussions of polycystic ovary syndrome. Gynecol Endocrinol 2010; 26(10): 708-11.
149. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998; 51(7): 581-6.
150. Papaioannou S, Tzafettas J. Anovulation with or without PCO, hyperandrogenaemia and hyperinsulinaemia as promoters of endometrial and breast cancer. Best Pract Res Clin Obstet Gynaecol 2010; 24(1): 19-27.
151. Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol 2005; 105(3): 575-80.
152. rd, Bergstralh EJ, Boardman LA, Keeney GL, et al. Risk factors for developing multiple malignancies in patients with endometrial cancer. Int J Gynecol Cancer 2011; 21(5): 896-901.
153. Berinder K, Akre O, Granath F, Hulting AL. Cancer risk in hyperprolactinemia patients: A population-based cohort study. Eur J Endocrinol 2011; 165(2): 209-15.
154. Mujagic Z, Srabovic N, Mujagic H. The role of prolactin in human breast cancer. Biochemia Medica 2009; 19(3): 236-49
155. Wolpert BJ, Amr S, Ezzat S, Saleh D, Gouda I, Loay I, et al. Estrogen exposure and bladder cancer risk in Egyptian women. Maturitas 2010; 67(4): 353-7.
156. Teras LR, Patel AV, Rodriguez C, Thun MJ, Calle EE. Parity, other reproductive factors, and risk of pancreatic cancer mortality in a large cohort of U.S. women. Cancer Causes Control 2005; 16(9): 1035-40.
157. Bosetti C, Negri E, Franceschi S, Conti E, Levi F, Tomei F. Risk factors for oral and pharyngeal cancer in women: A study from Italy and Switzerland. Br J Cancer 2000; 82(1): 204-7.
158. Key TJ. Hormones and cancer in humans. Mutat Res 1995; 333(1-2): 59-67.
159. Britt K, Ashworth A, Smalley M. Pregnancy and the risk of breast cancer. Endocr Relat Cancer 2007; 14(4): 907-33.
160. Lay YC, Hamazaki K, Yoshizawa K, Kawanaka A, Kuwata M, Kanematsu S, et al. Short-term pregnancy hormone treatment of Nmethyl-N-nitrosourea-induced mammary carcinogenesis in relation to fatty acid composition of serum phospholipids in female Lewis rats. In vivo 2010; 24(4): 553-60.
161. Opdahl S, Alsaker MD, Janszky I, Romundstad PR, Vatten LJ. Joint effect of nulliparity and other breast cancer risk factors. Br J Cancer 2011; 105(5): 731-6.
162. Newcomb PA, Trentham-Dietz A, Hampton JM, Egan KM, Titus-Ernstoff L, Warren Andersen S, et al. Late age at full term birth is strongly associated with lobular breast cancer. Cancer 2011; 117(9): 1946-56.
163. Cetin I, Cozzi V, Antonazzo P. Infertility as a cancer risk factor-a review. Placenta 2008; 29(Suppl B): 169-77.
164. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Risk of breast cancer in a cohort of infertile women. Gynecol Oncol 1996; 60(1): 3-7.
165. Källén B, Finnström O, Lindam A, Nilsson E, Nygren KG, Olausson PO. Malignancies among women who gave birth after in vitro fertilization. Hum Reprod 2011; 26(1): 253-8.
166. Schneider JG, Tompkins C, Blumenthal RS, Mora S. The metabolic syndrome in women. Cardiol Rev 2006; 14(6): 286-91.
167. Tchernof A, Calles-Escandon J, Sites CK, Poehlman ET. Menopause, central body fatness and insulin resistance: Effects of hormone-replacement therapy. Coron Artery Dis 1998; 9(8): 503-11.
168. Deligeoroglou E, Michailidis E, Creatsas G. Oral contraceptives and reproductive system cancer. Ann NY Acad Sci 2003; 997: 199-208.
169. ESHRE Capri Workshop Group. Ovarian and endometrial function during hormonal contraception. Hum Reprod 2001; 16(7): 1527-35.
170. Tejura, B. Methods of treating hyperandrogenism and conditions associated therewith by administering a fatty acid ester of an estrogen or an estrogen derivative. US20100286105 (2010).
171. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Wrighting Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288(3): 321-33.
172. Suba Z. Re-evaluation of the Epidemiological Associations of female Sexual Steroids and Cancer Risk. In: Suba Z. Ed. Estrogen versus Cancer. New-York, Nova Science Publishers Inc., 2009, pp. 107-126.
173. LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy. A randomized controlled trial. JAMA 2011; 305(13): 1305-14.
174. Shapiro S, Farmer RD, Mueck AO, Seaman H, Stevenson JC. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: Part 3. The Women's Health Initiative: Unopposed estrogen. J Fam Plann Reprod Health Care 2011; 37(4): 225-30.
175. Ragaz J, Shakeraneh S. Estrogen Prevention of Breast Cancer: A Critical Review. In: Suba Z. Ed. Estrogen Prevention for Breast Cancer. New York, Nova Science Publishers Inc., 2012.
176. Howell A, Evans GD. Hormone replacement therapy and breast cancer. Recent Results Cancer Res 2011; 188: 115-24.
177. Chlebowski RT, Anderson GL. Changing concepts: Menopausal hormone therapy and breast cancer. J Natl Cancer Inst 2012; 104(7): 517-27.
178. Stevenson JC, Hodis HN, Pickar JH, Lobo RA. HRT and breast cancer risk: A realistic perspective. Climacteric 2011; 14(6): 633-6.
179. Darbre PD, Charles AK. Environmental oestrogens and breast cancer: Evidence for combined involvement of dietary, household and cosmetic xenoestrogens. Anticancer Res 2010; 30(3): 815-27.
180. Jung EM, An BS, Yang H, Choi KC, Jeung EB. Biomarker genes for detecting estrogenic activity of endocrine disruptors via estrogen receptors. Int J Environ Res Public Health 2012; 9(3): 698-711.
181. Suba Z. Light deficiency confers breast cancer risk by endocrine disorders. Recent Pat Anticancer Drug Discov 2012; 7(3): 337-44.
182. Suba Z. Antiestrogen or Estrogen as Anticancer Drug. In: Hoffmann AB. Ed. Sex Hormones: Development, Regulation and Disorders. New York, Nova Science Publishers Inc., 2011, pp. 75-94.
183. Leick MB, Jordan VC. Evolution of Estrogen Action in Breast Cancer: From Culprit to Killer. In: Suba Z. Ed. Estrogen prevention for breast cancer. New York, Nova Science Publishers Inc., 2012.
184. Kelly, G.E. Methods for treating or reducing predisposition to breast cancer, premenopausal syndrome or symptoms associated with menopause by administration of phyto-estrogen. US6562380 (1997).
185. Kotake, Y., Nlijima, J., Fukuda, Y., Nagai, M., Kanada, R.M., Nakashima, T., Yoshida, M., Tsuchida, T. Novel physiologically active substances. US20080275059 (2008).
186. Schwartz, A.G., Lewbart, M.L. Steroids useful as anti-cancer and anti-obesity agents. US5696106 (1997).